A Phase 2 interventional study of Islatravir and Placebo in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection
This study is ongoing for collection of safety follow-up of infants born to mothers participating in the study. The present results are based on the Week 68 interim analysis.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapies from 30 days prior to Day
1 through the duration of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
Drug: Islatravir · Drug: Placebo
120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
Drug: Islatravir
Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
Drug: Placebo
Islatravir 30 mg capsules taken by mouth.
Also known as: MK-8591
Placebo capsules taken by mouth.
Number of Participants With ≥1 Adverse Event (AE) Through Week 36
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 36 weeks
Number of Participants Discontinuing From Study Therapy Due to AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 20 weeks
Number of Participants Discontinuing From Study Therapy Due to ≥1 Drug-related AE
A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study therapy.
Time frame: Up to 20 weeks
Number of Participants With ≥1 Drug-related AE Through Week 36
A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.
Time frame: Up to 36 weeks
Number of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36
An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.
Time frame: Up to 36 weeks
Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 36
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').
Time frame: Up to 36 weeks
Number of Participants With ≥1 Drug-related SAE Through Week 36
An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.
Time frame: Up to 36 weeks
Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 36
A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).
Time frame: Up to 36 weeks
Number of Participants With an AE Resulting in Death Through Week 36
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 36 weeks
Area Under the Plasma Concentration-time Curve From Dosing to 672 Hours Postdose (AUC0-672) of Plasma ISL
The AUC0-672 of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
Time frame: Day 1 and Day 140: predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.
Maximum Plasma Concentration (Cmax) of ISL
The Cmax of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
Time frame: Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.
Trough Plasma Concentration (Ctrough) of ISL
The plasma Ctrough of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
Time frame: Day 1 and Week 20: predose and 30-min postdose. Day 2: 24 hours post Day 1 dose. Weeks 1, 2, 3, 21, 22, 23 and 24: any time during the study visit. Weeks 4, 8, 12 and 16: predose.
Apparent Plasma Terminal Half-life (t1/2) of ISL
The plasma t1/2 of ISL after dosing on Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
Time frame: Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.
Number of Participants With ≥1 AE Through Week 24
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 24 weeks
Number of Participants With ≥1 Drug-related AE Through Week 24
A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.
Time frame: Up to 24 weeks
Number of Participants With ≥1 SAE Through Week 24
An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.
Time frame: Up to 24 weeks
Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 24
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').
Time frame: Up to 24 weeks
Number of Participants With ≥1 Drug-related SAE Through Week 24
An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.
Time frame: Up to 24 weeks
Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 24
A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).
Time frame: Up to 24 weeks
Number of Participants With an AE Resulting in Death Through Week 24
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 24 weeks
Healthy HIV-uninfected male and female participants were enrolled at 9 study centers in 3 countries.
| Milestone | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Started | 97 | 97 | 48 |
| Completed | 82 | 91 | 45 |
| Not completed | 15 | 6 | 3 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 2 |
| Withdrew: Withdrawal by subject | 10 | 1 | 1 |
| Withdrew: Status not recorded | 0 | 2 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Adverse Event (AE) Through Week 36 | 66 | 63 | 36 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants Discontinuing From Study Therapy Due to AE | 1 | 1 | 0 |
A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study therapy.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants Discontinuing From Study Therapy Due to ≥1 Drug-related AE | 1 | 1 | 0 |
A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Drug-related AE Through Week 36 | 9 | 14 | 12 |
An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Serious Adverse Event (SAE) Through Week 36 | 1 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 36 | 5 | 4 | 1 |
An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Drug-related SAE Through Week 36 | 0 | 0 | 0 |
A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 36 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With an AE Resulting in Death Through Week 36 | 0 | 0 | 0 |
The AUC0-672 of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
| hr*umol/L | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Day 1 | 7.88 ± 56.8 | 16.6 ± 50.5 | — |
| Day 140 | 21.2 ± 140.3 | 37.6 ± 136.6 | — |
The Cmax of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
| µmol/L | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Day 1 | 0.387 ± 279.9 | 0.954 ± 186.2 | — |
| Day 140 | 0.376 ± 597.7 | 0.792 ± 349.6 | — |
The plasma Ctrough of ISL after dosing on Day 1 and Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
| µmol/L | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Day 1 | 0.000556 ± 36.6 | 0.00101 ± 37.0 | — |
| Day 140 | 0.000809 ± 37.0 | 0.000124 ± 42.0 | — |
The plasma t1/2 of ISL after dosing on Day 140 is reported. Only ISL-treated participants are included in the PK analysis.
| Hours | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Day 1 | NA ± NA | NA ± NA | — |
| Day 140 | 175 ± 16.2 | 177 ± 19.8 | — |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 AE Through Week 24 | 58 | 60 | 32 |
A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Drug-related AE Through Week 24 | 9 | 14 | 12 |
An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 SAE Through Week 24 | 1 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study therapy, whether or not considered related to the study intervention. Toxicity grading was according to the National Institutes of Health Division of AIDS (NIH DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (Grade 3 is 'severe'; Grade 4 is 'potentially life-threatening'; and Grade 5 'results in death').
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With a ≥1 Grade 3 to Grade 5 AE up to Week 24 | 3 | 3 | 1 |
An drug-related SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is an other important medical event, that is considered related to study therapy.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Drug-related SAE Through Week 24 | 0 | 0 | 0 |
A drug-related Grade 3 to Grade 5 AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention; has a toxicity Grade 3 (severe), 4 (potentially life-threatening), or 5 (results in death); and is considered related to study therapy. Toxicity grading was according to the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 2.1).
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With ≥1 Drug-related Grade 3 to 5 AE Through Week 24 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Number of Participants With an AE Resulting in Death Through Week 24 | 0 | 0 | 0 |
Collected over Up to 36 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Islatravir 60 mg | 1/97 (1%) | 1/97 (1%) | 24/97 (24.7%) |
| Islatravir 120 mg | 0/97 (0%) | 0/97 (0%) | 23/97 (23.7%) |
| Placebo | 0/48 (0%) | 0/48 (0%) | 16/48 (33.3%) |
| Event | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| Intentional self-injuryPsychiatric disorders | 1/97 | 0/97 | 0/48 |
| Loss of consciousnessNervous system disorders | 1/97 | 0/97 | 0/48 |
| Event | Islatravir 60 mg | Islatravir 120 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 10/97 | 9/97 | 2/48 |
| Abdominal painGastrointestinal disorders | 3/97 | 3/97 | 4/48 |
| DiarrhoeaGastrointestinal disorders | 5/97 | 4/97 | 4/48 |
| NauseaGastrointestinal disorders | 5/97 | 7/97 | 2/48 |
| Upper respiratory tract infectionInfections and infestations | 4/97 | 4/97 | 3/48 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/97 | 1/97 | 3/48 |
| Alanine aminotransferase increasedInvestigations | 2/97 | 0/97 | 3/48 |
| DizzinessNervous system disorders | 2/97 | 0/97 | 3/48 |
| Blood pressure increasedInvestigations | 1/97 | 5/97 | 0/48 |
| Age, Continuous(Years) | Islatravir 60 mg | Islatravir 120 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 33.6 ± 9.9 | 33.2 ± 9.7 | 30.9 ± 7.9 | 32.9 ± 9.5 |
| Sex: Female, Male(Participants) | Islatravir 60 mg | Islatravir 120 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 66 | 64 | 33 | 163 |
| Male | 31 | 33 | 15 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Islatravir 60 mg | Islatravir 120 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 19 | 9 | 8 | 36 |
| Not Hispanic or Latino | 78 | 88 | 40 | 206 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Islatravir 60 mg | Islatravir 120 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 37 | 48 | 16 | 101 |
| White | 55 | 44 | 29 | 128 |
| More than one race | 5 | 3 | 3 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2019 to primary completion in Mar 2022, 29 months.
Results were first posted in Mar 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Islatravir